122 related articles for article (PubMed ID: 23713890)
1. Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.
von Heideman A; Tholander B; Grundmark B; Cajander S; Gerdin E; Holm L; Axelsson A; Rosenberg P; Mahteme H; Daniel E; Larsson R; Nygren P
Acta Oncol; 2014 Feb; 53(2):242-50. PubMed ID: 23713890
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer.
Lee SW; Kim YM; Kim MB; Kim DY; Kim JH; Nam JH; Kim YT
Acta Med Okayama; 2012; 66(3):271-7. PubMed ID: 22729108
[TBL] [Abstract][Full Text] [Related]
4. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.
Moraya AI; Ali JL; Samadder P; Liang L; Morrison LC; Werbowetski-Ogilvie TE; Ogunsina M; Schweizer F; Arthur G; Nachtigal MW
J Exp Clin Cancer Res; 2017 May; 36(1):67. PubMed ID: 28499442
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
7. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.
Yildiz I; Tas F; Kilic L; Sen F; Saip P; Eralp Y; Keskin S; Karabulut S; Ciftci R; Serilmez M; Yasasever V; Aydiner A
Cancer Chemother Pharmacol; 2013 Aug; 72(2):437-44. PubMed ID: 23801282
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
10. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.
Matsushita Y; Yokoyama Y; Yoshida H; Osawa Y; Mizunuma M; Shigeto T; Futagami M; Imaizumi T; Mizunuma H
J Ovarian Res; 2014 Nov; 7():107. PubMed ID: 25424877
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
12.
Bjersand K; Blom K; Poromaa IS; Stålberg K; Lejon AM; Bäckman F; Nyberg Å; Andersson C; Larsson R; Nygren P
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 36082820
[TBL] [Abstract][Full Text] [Related]
13. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
14. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
15. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
16. Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.
Pastò A; Pagotto A; Pilotto G; De Paoli A; De Salvo GL; Baldoni A; Nicoletto MO; Ricci F; Damia G; Bellio C; Indraccolo S; Amadori A
Oncotarget; 2017 Jan; 8(4):6433-6445. PubMed ID: 28031535
[TBL] [Abstract][Full Text] [Related]
17. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
18. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
19. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
20. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
